Clinical And Ultrasonographic Profile Of Adalimumab-Treated Hidradenitis Suppurativa Patients: A Real-Life Monocentric Experience

Dermato-Venereologica Ultrasonography has proven useful for diagnosis and treatment monitoring in patients with hidradenitis sup-purativa. The aim of this study was to assess the clini-cal response to adalimumab using ultrasound findings. This prospective study collected data on demographic features, disease severity, and hidradenitis suppura-tiva findings from patients with hidradenitis suppura-tiva treated with adalimumab. Generalized estimating equations investigated relationships between disease severity measures and clinical/demographic variables. The study included a total of 41 patients with hidra-denitis suppurativa who were treated with adalimu-mab for a mean +/- SD period of 50.8 +/- 32.2 weeks; range 6-108 weeks). Clinical improvement was observed during adalimumab therapy, with a progressively gre-ater number of patients achieving HiSCR50 response (36.4% at week 52). Disease duration was identified as the most relevant clinical variable affecting disease severity and treatment response. Treatment response was also influenced by treatment duration, with a 4% greater likelihood of achieving HiSCR50 response at each time-point. At the ultrasound examination, sub-cutaneous involvement of hidradenitis suppurativa lesions was identified as a predictive negative factor for clinical response to adalimumab (HiSCR50 achie-vement).